Picture of Sinovac Biotech logo

SVA — Sinovac Biotech Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareMicro Cap

Annual cashflow statement for Sinovac Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

C2021
December 31st
R2022
December 31st
R2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:20-F20-F20-F20-F20-F
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line14,120-60-12140.7-199
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items44129-122-31.252.2
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital562-941238-123-377
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities15,322-798139-56.9-512
Capital Expenditures-594-314-156-97.6-49.1
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-2,381-5,780-2,5435544,437
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-2,975-6,094-2,6994564,388
Financing Cash Flow Items-1,876-235-328-947-3,534
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-1,913-300-88.6-824-3,435
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash10,570-7,733-2,758-527554